 It is debated whether these preparations actually lead to TRPV1 desensitization; it is possible that they act via counter-irritation.Novel preparations containing higher capsaicin concentration (up to 10%) are under clinical trials.Eight percent capsaicin patches have recently become available for clinical use, with supporting evidence demonstrating that a 30-minute treatment can provide up to 3 months analgesia by causing regression of TRPV1-containing neurons in the skin.